ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC
The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC treatment paradigm.
The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC treatment paradigm.
What's Your Reaction?
